The main objective of this project is to assess the average cost of the treatment of bleeding postpartum with recombinant activated factor VII (NovoSeven®) and compare it to the reference strategy. Costs related to medicine NovoSeven® can generate surplus, but it also avoids in some cases very costly invasive procedures. It will be interesting to compare the average cost of the complete strategies supported.

Inclusion Criteria:

• Severe haemorrhage is defined by the following criteria: blood loss greater than 1500 ml graduated measured in the bag and / or hemodynamically unstable and / or requiring transfusion of packed red blood cells (3);
• Sulprostone (Nalador®) ineffective;
• Age over 18 years;
• The term is more than 27 SA (child's viability);
• Without anthropomorphic limit;
• The outcome of the pregnancy is normal or pathological;
• Informed consent "emergency procedure" is signed by the husband or family.

Exclusion Criteria:

• minors, majors in guardianship, with a personal history of venous or arterial thrombosis may cons-indicate treatment with rFVIIa or refuses to sign the consent

The population of this study is the population described in "rhuFVIIa in Post-partum Hemorrhage " NCT00370877